Why do rising life expectancies increase the need for cost-effective health care solutions?

Rising life expectancies have led to a significant increase in the prevalence of chronic disease, which currently accounts for more than 70 percent of health care spending in most developed countries. Because treatments for these conditions are often prolonged, costly, and frequently ineffective, the continued rise in their prevalence threatens to push health care spending to unsustainable levels relative to the gross national product.1

In the context of translational medicine, there is an urgent need for cost-effective solutions to address this financial burden. Translational medicine aims to improve this situation by:

• Expediting Clinical Trials: By incorporating novel surrogate endpoints—biological markers that assess treatment benefits early—translational medicine can significantly shorten the duration of clinical trials for chronic disease treatments.1
• Improving Preclinical Screening: Current models often lack predictive accuracy, leading to high costs and failures in drug development. Translational medicine facilitates the transfer of testable agents into the clinic more rapidly, reducing the costs associated with preclinical testing.1
• Advancing Personalized Medicine: By linking an individual's genetic background to their disease predisposition and treatment responsiveness, researchers expect to develop more cost-efficient, patient-specific therapeutic interventions.1